Stockscreener 앱 받기
27.50
0.07%
-0.01
전일 마감가:
$27.51
열려 있는:
$26.95
하루 거래량:
10.22M
Relative Volume:
0.31
시가총액:
$6.35B
수익:
$2.35B
순이익/손실:
$128.37M
주가수익비율:
52.67
EPS:
0.5221
순현금흐름:
$57.42M
1주 성능:
+9.09%
1개월 성능:
+0.29%
6개월 성능:
-25.84%
1년 성능:
-49.77%
1일 변동 폭
$25.71
$28.04
1주일 범위
$24.13
$28.39
52주 변동 폭
$13.74
$70.43
Hims Hers Health Inc Stock (HIMS) Company Profile
명칭
Hims Hers Health Inc
전화
415-851-0195
주소
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
27.45 | 6.37B | 2.35B | 128.37M | 57.42M | 0.5221 |
TAK
Takeda Pharmaceutical Co Adr
|
15.01 | 47.96B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
8.73 | 38.49B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.84 | 38.52B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
77.60 | 32.02B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
547.44 | 22.92B | 3.17B | 1.29B | 1.01B | 27.09 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-24 | 개시 | JP Morgan | Overweight |
| 2026-03-10 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2026-03-10 | 업그레이드 | Citigroup | Sell → Neutral |
| 2026-03-09 | 업그레이드 | Needham | Hold → Buy |
| 2026-02-24 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2026-01-12 | 개시 | Evercore ISI | In-line |
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-10-21 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | 다운그레이드 | Needham | Buy → Hold |
| 2025-06-04 | 재확인 | Needham | Buy |
| 2025-04-29 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-02-18 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2025-01-07 | 개시 | BTIG Research | Buy |
| 2024-12-17 | 개시 | Morgan Stanley | Overweight |
| 2024-11-14 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2024-08-22 | 개시 | Needham | Buy |
| 2024-08-09 | 다운그레이드 | Imperial Capital | Outperform → In-line |
| 2024-05-22 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-04-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-04-10 | 개시 | Canaccord Genuity | Buy |
| 2024-02-28 | 업그레이드 | Imperial Capital | In-line → Outperform |
| 2024-02-26 | 개시 | Leerink Partners | Market Perform |
| 2023-12-07 | 개시 | Imperial Capital | In-line |
| 2023-07-28 | 개시 | TD Cowen | Outperform |
| 2023-04-11 | 개시 | Robert W. Baird | Neutral |
| 2023-02-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-11-08 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-11-08 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | 개시 | Truist | Hold |
| 2022-07-15 | 개시 | SVB Leerink | Underperform |
| 2022-04-14 | 개시 | Guggenheim | Buy |
| 2022-04-01 | 재개 | Credit Suisse | Outperform |
| 2022-03-10 | 개시 | Deutsche Bank | Hold |
| 2021-12-02 | 개시 | Jefferies | Hold |
| 2021-11-11 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | 개시 | BofA Securities | Neutral |
| 2021-05-20 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | 개시 | Truist | Hold |
| 2021-03-09 | 개시 | Credit Suisse | Neutral |
| 2021-03-02 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-02-17 | 개시 | Citigroup | Neutral |
| 2021-02-12 | 개시 | Piper Sandler | Neutral |
| 2021-02-08 | 개시 | Tigress Financial | Buy |
모두보기
Hims Hers Health Inc 주식(HIMS)의 최신 뉴스
10 Health Care Stocks Whale Activity In Today's Session - Benzinga
CCORF Maintains Hims & Hers Health(HIMS.US) With Buy Rating, Maintains Target Price $32 - 富途牛牛
HIMS Stock Slips Despite Early Eucalyptus Buyout Close: Analyst Sees 10% Downside On GLP-1 Profit Risks - Stocktwits
Most and least shorted mid- to mega-cap healthcare stocks at the end of May - Seeking Alpha
Canaccord reiterates Hims & Hers stock Buy rating on peptide growth - Investing.com
Taking A Fresh Look At Hims & Hers Health (HIMS) Valuation After Recent Share Price Swings - Yahoo Finance
Political Scrutiny Tests Hims And Hers GLP1 Weight Loss Growth Story - Yahoo Finance
Hims And Hers Expands Globally With Eucalyptus Deal And Valuation Gap - simplywall.st
HIMS stock slips despite early eucalyptus buyout close: Analyst sees 10% downside on GLP-1 profit risks - MSN
Hims & Hers Health Options Spot-On: On June 2nd, 101.18K Contracts Were Traded, With 1.04 Million Open Interest - Moomoo
EXCLUSIVE: Sen. Jim Banks wants FDA and FTC to investigate whether Hims & Hers is undermining TrumpRx - Washington Reporter
HIMS: 2030 targets hinge on global expansion, AI-driven care, and integrated specialty growth - TradingView
Hims & Hers Expands With Eucalyptus Acquisition - TradingView
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Hims & Hers Health, Inc. completed the acquisition of EUC Management Pty Ltd. - marketscreener.com
Leerink maintains Hims and Hers stock rating on acquisition timing - Investing.com
HIMS Expands Global Reach with Eucalyptus Acquisition - GuruFocus
Hims & Hers Completes Acquisition of Eucalyptus, Parent Company of Juniper, Officially Entering Japanese Market - 01net
Hims & Hers Closes Eucalyptus Deal, Expands Global Platform - TipRanks
Hims & Hers Amends Revolving Credit Agreement With JPMorgan to Support Eucalyptus Deal - TradingView
Hims And Hers Health Expands With Eucalyptus Acquisition And Global Growth Prospects - Yahoo Finance
Hims & Hers (NYSE: HIMS) expands with Eucalyptus deal and 2030 growth targets - Stock Titan
Hims & Hers completes acquisition of Eucalyptus in Australia - Investing.com Australia
Hims & Hers completes acquisition of Eucalyptus, enters Japan By Investing.com - Investing.com Australia
Press Release: Hims & Hers Completes Acquisition of Eucalyptus, Expanding Access to Comprehensive, Clinically-Backed Weight Management Care in Germany - Moomoo
Hims & Hers completes acquisition of Juniper parent Eucalyptus - Investing.com
Hims & Hers completes acquisition of Eucalyptus - Investing.com
Hims & Hers completes acquisition of Eucalyptus in Germany By Investing.com - Investing.com Canada
Hims & Hers Completes Acquisition of Eucalyptus, Advancing its Position as the World’s Largest Consumer Health Platform - HIMS Investor Relations
How We’re Reimagining The Future of Health for Hundreds of Millions of People - Hims & Hers Newsroom
Hims & Hers Completes Acquisition of Eucalyptus, Expanding Access to Comprehensive, Clinically-Backed Weight Management Care in Germany - Eagle-Tribune
Hims & Hers Completes Acquisition of Eucalyptus, Advancing Position as the World's Largest Consumer Health Platform - standard-journal.com
Hims & Hers Completes Acquisition of Eucalyptus, Accelerating Its Push to Transform Healthcare for Canadians - New Castle News
$Hims & Hers Health (HIMS.US)$ come on break that 31.5ish orange line so we can go up to upper green - Moomoo
LULU Settles With Wilson, HIMS and CHWY Value Picks - Gotrade
Is Hims & Hers Stock an Undervalued Stock to Buy? - The Motley Fool
Is Hims & Hers Stock an Undervalued Stock to Buy? - The Motley Fool
HIMS Stock Eyes Breakout Week: Eight New Partners Fuel Push To Build An All-In-One Health Platform - Stocktwits
Hims & Hers Health Options Spot-On: On June 1st, 185.47K Contracts Were Traded, With 1.08 Million Open Interest - Moomoo
$Hims & Hers Health (HIMS.US)$ - Moomoo
Lead Independent Director of Hims & Hers Health David Wells Buys 27% More Shares - simplywall.st
$Hims & Hers Health (HIMS.US)$ Not bad! About one year plus with HIMs and it never failed me. - Moomoo
$Hims & Hers Health (HIMS.US)$ that’s what I’m talking about $Hims & Hers Health (HIMS.US)$ 📈 - Moomoo
PPI Report April 2026: How Inflation Data Is Moving HIMS, CEG, and PLUG Stock Today - TradingKey
Hims & Hers Health Stock (HIMS) Opinions on technical resistance levels - Quiver Quantitative
HIMS stock eyes breakout week: Eight new partners fuel push to build an all-in-one health platform - MSN
Hims Hers Health Inc (HIMS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.05%
1.34%
자본화:
|
볼륨(24시간):